Cagrilintide Powder

Cagrilintide Powder 98%  High-purity Peptide Raw Materials Supplier

YTBIO offers high-purity Cagrilintide (98%), manufactured under a rigorous quality control system to ensure product purity, stability, and batch-to-batch consistency.

What is Cagrilintide?

Cagrilintide Powder is a long-acting amylin analogue that is injected subcutaneously once a week. Canaglitide mimics amylin, a hormone produced by the pancreas and secreted by pancreatic beta cells along with insulin after food intake. It is involved in satiety regulation through activity in the brain and improves glycemic control by delaying gastric emptying and inhibiting glucagon secretion.

Cagrilintide reduces energy intake and modulates food choices and preferences; it exerts a glucose-regulating effect through co-secretion with insulin, inhibits postprandial glucagon release, and delays gastric emptying. It offers significant advantages in the treatment of diabetes, obesity, metabolic syndrome, and cardiovascular disease, presenting broad prospects for clinical application.

Why Choose YTBIO?

YTBIO has established a rigorous quality management system for peptides, exercising comprehensive control over purity, impurities, and batch consistency to meet your requirements for high-quality raw materials.

We utilize quality control methods such as HPLC to ensure product purity and stability.

Product specifications, Certificates of Analysis (COA), and relevant technical documentation are available upon request.

We hold multiple international certifications, including cGMP, ISO9001, ISO22000, FSSC22000, BRC, Kosher, and Halal.

With 12 years of industry experience and our own 10,000-square-meter manufacturing facility, we provide stable product supplies and services to customers worldwide.

Test Report

Key Physiological Activities

1. Weight Management

Suppresses appetite and reduces food intake

Delays gastric emptying and prolongs the sensation of satiety

Promotes a negative energy balance and facilitates fat metabolism

2. Blood Glucose Regulation

Inhibits excessive glucagon secretion, preventing excessive postprandial blood glucose spikes

Works synergistically with insulin to optimize glucose homeostasis

Significantly improves glycated hemoglobin (HbA1c) levels in patients with type 2 diabetes

3. Intervention for Metabolic Syndrome

Clinical studies show trends of improvement in metabolic markers such as blood pressure and blood lipids

Helps reduce the risk of obesity-related comorbidities

Experiments on Cagrilintide

Obesity is a chronic disease that requires long-term treatment. It increases the risk of type 2 diabetes, hypertension, and cardiovascular disease, or leads to a series of complications, which in turn affects life expectancy and reduces quality of life. For overweight or obese people, lifestyle intervention is the preferred treatment, but some patients still cannot achieve the expected weight loss goals for various reasons and need to lose weight with the help of drugs.

At present, GLP-1 receptor agonists such as liraglutide and semaglutide have been approved by the US FDA for the treatment of specific obese patients. GLP-1 is a hormone secreted by intestinal cells. In addition to stimulating insulin secretion and inhibiting glucagon secretion to promote blood sugar metabolism, it can also delay gastric emptying and suppress appetite.

In addition to the GLP-1 signaling pathway, researchers are also trying to simulate the effects of other hormones related to hunger and satiety. One of them is amylin, a hormone that stimulates satiety. Cagrilintide is the first long-acting amylin analogue studied for weight management. What are its efficacy and safety?

Recently, Professor David C W Lau and his team from the Cumming School of Medicine at the University of Calgary in Canada published a major article in the top medical journal The Lancet, reporting the preliminary efficacy and safety tolerability of cagrilintide in weight management for overweight and obese people.

The results showed that as an adjunct to lifestyle intervention, once-weekly injections of cagrilintide treatment can reduce the average weight by up to 11.5 kg after 26 weeks, and it is safe and tolerable, which is expected to provide a new solution for weight loss treatment.

The study is a multicenter, randomized, double-blind, placebo-controlled and positive-controlled, dose-finding Phase 2 trial conducted in 57 research centers in 10 countries including Canada, Japan, the United Kingdom and the United States. Subjects met the following criteria:

• Age ≥ 18 years, no diabetes;
• Body mass index (BMI) ≥ 30kg/m2; or BMI ≥ 27kg/m2, and hypertension or dyslipidemia.

From March 1 to August 19, 2019, the study included a total of 706 subjects, who were randomly assigned to the drug group or the placebo group in a 6:1 ratio:

• Subcutaneous injection of cagrilintide once a week, divided into 5 dose groups (0.3mg, 0.6mg, 1.2mg, 2.4mg, 4.5mg): 100-102 people in each group;
• Subcutaneous injection of liraglutide 3.0mg once a day: 99 people;
• Dose-matched placebo group: 101 people.

The study lasted for 32 weeks, with a 26-week treatment period (including a 6-week dose escalation period) and a 6-week follow-up period without treatment.
The primary endpoint of the study was the percentage change in body weight from baseline to week 26, and the treatment effect was evaluated for all randomized participants. Safety was evaluated for all participants who received at least one dose of randomized treatment.

Safe And Effective For Long-term Weight Management In People With Overweight Or Obesity

Weight change by treatment group: More patients in the cagrilintide 4.5 mg group (purple) lost more than 5%, 10%, and 15% of their body weight compared with liraglutide (red)

• Permanent discontinuation of treatment (n=73 [10%]) occurred at similar rates across treatment groups, primarily due to adverse events (n=30 [4%]). A total of 29 participants (4%) withdrew from the trial.
• Based on trial drug assessments (assuming all participants adhered to treatment throughout the trial), mean percent weight loss was greater for all doses of cagrilintide (0.3 mg-4.5 mg, 6.0%-10.8% [6.4 kg -11.5 kg]) compared with placebo (3.0% [3.3 kg]). Participants in the cagrilintide 4.5 mg group also lost more weight than those in the liraglutide 3.0 mg group (10.8% [11.5 kg] vs 9.0% [9.6 kg]).
• Similar weight loss results were observed based on treatment strategy assessment (regardless of whether participants interrupted or withdrew from treatment).
• In terms of safety, the most common adverse events were gastrointestinal dysfunction (such as nausea, constipation, and diarrhea) and administration site reactions. Compared with the placebo group, the proportion of participants who injected cagrilintide 0.3 mg-4.5 mg experienced gastrointestinal adverse events more frequently (41%–63% vs 32%), mainly nausea (20%-47% vs 18%).

The study showed that cagrilintide treatment can significantly reduce weight and is well tolerated in overweight and obese patients. At the same time, different doses of cagrilintide have significant effects on body weight. The results of this experiment provide a scientific basis for further conducting Phase 3 trials. In the future, in-depth research can be conducted on the effects of higher doses of cagrilintide.

Contact Us

Yuantai Organic Bio is committed to providing customers with the highest-quality Cagrilintide Powder 98% and services so that every consumer can enjoy natural, healthy, and high-quality food. If you have any inquiries or needs about our products, please feel free to contact us, and we will reply to you as soon as possible.

​Tel:86-029-86478251 / 86-029-86119593

Whatsapp:8617782577059

Email:sales@sxytorganic.com